The Src homology 3 binding domain is required for lysophosphatidic acid 3 receptor-mediated cellular viability in melanoma cells

被引:12
作者
Jia, Wei [1 ]
Tran, Sterling K. [1 ]
Ruddick, Caitlin A. [1 ]
Murph, Mandi M. [1 ]
机构
[1] Univ Georgia, Coll Pharm, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA
关键词
Lysophosphatidic acid; LPA(3); SH3; domain; OVARIAN-CANCER CELLS; MOLECULAR-CLONING; GROWTH; PROTEIN; MOUSE; CHEMORESISTANCE; AUTOTAXIN; PATHWAYS; MOTILITY; GAMMA;
D O I
10.1016/j.canlet.2014.10.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The LPA(3) receptor is a G protein-coupled receptor that binds extracellular lysophosphatidic acid and mediates intracellular signaling cascades. Although we previously reported that receptor inhibition using siRNA or chemical inhibition obliterates the viability of melanoma cells, the mechanism was unclear. Herein we hypothesized that amino acids comprising the Src homology 3 (SH3) ligand binding motif, R/K-X-X-V/P-X-X-P or (216)-KTNVLSP-(222), within the third intracellular loop of LPA(3) were critical in mediating this outcome. Therefore, we performed site-directed mutagenesis of the lysine, valine and proline, replacing these amino acids with alanines, and evaluated the changes in viability, proliferation, ERK1/2 signaling and calcium in response to lysophosphatidic acid. Our results show that enforced LPA(3) expression in SK-MEL-2 cells enhanced their resiliency by allowing these cells to oppose any loss of viability during growth in serum-free medium for up to 96 h, in contrast to parental SK-MEL-2 cells, which show a significant decline in viability. Similarly, site-directed alanine substitutions of valine and proline, V219A/P222A or 2aa-SK-MEL-2 cells, did not significantly alter viability, but adding a further alanine to replace the lysine, K216A/V219A/P222A or 3aa-SK-MEL-2 cells, obliterated this function. In addition, an inhibitor of the LPA(3) receptor had no impact on the parental SK-MEL-2, 2aa-SK-MEL-2 or 3aa-SK-MEL-2 cells, but significantly reduced viability among wt-LPA3-SK-MEL-2 cells. Taken together, the data suggest that the SH3 ligand binding domain of LPA(3) is required to mediate viability in melanoma cells. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:589 / 596
页数:8
相关论文
共 30 条
[1]   PROLINE-RICH SEQUENCES THAT BIND TO SRC HOMOLOGY-3 DOMAINS WITH INDIVIDUAL SPECIFICITIES [J].
ALEXANDROPOULOS, K ;
CHENG, GH ;
BALTIMORE, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (08) :3110-3114
[2]   Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid [J].
Altman, Molly K. ;
Gopal, Vashisht ;
Jia, Wei ;
Yu, Shuangxing ;
Hall, Hassan ;
Mills, Gordon B. ;
McGinnis, A. Cary ;
Bartlett, Michael G. ;
Jiang, Guowei ;
Madan, Damian ;
Prestwich, Glenn D. ;
Xu, Yong ;
Davies, Michael A. ;
Murph, Mandi M. .
MOLECULAR CANCER, 2010, 9
[3]  
Bae I, 1996, CANCER RES, V56, P840
[4]   Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo [J].
Balazs, L ;
Okolicany, J ;
Ferrebee, M ;
Tolley, B ;
Tigyi, G .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2001, 280 (02) :R466-R472
[5]   Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid [J].
Bandoh, K ;
Aoki, J ;
Hosono, H ;
Kobayashi, S ;
Kobayashi, T ;
Murakami-Murofushi, K ;
Tsujimoto, M ;
Arai, H ;
Inoue, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (39) :27776-27785
[6]   International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature [J].
Chun, Jerold ;
Hla, Timothy ;
Lynch, Kevin R. ;
Spiegel, Sarah ;
Moolenaar, Wouter H. .
PHARMACOLOGICAL REVIEWS, 2010, 62 (04) :579-587
[7]   The mouse lpA3/Edg7 lysophosphatidic acid receptor gene:: genomic structure, chromosomal localization, and expression pattern [J].
Contos, JJA ;
Chun, J .
GENE, 2001, 267 (02) :243-253
[8]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[9]   Lysophosphatidic acid enhances healing of acute cutaneous wounds in the mouse [J].
Demoyer, JS ;
Skalak, TC ;
Durieux, ME .
WOUND REPAIR AND REGENERATION, 2000, 8 (06) :530-537
[10]   Structure-based drug design identifies novel LPA3 antagonists [J].
Fells, James I. ;
Tsukahara, Ryoko ;
Liu, Jianxiong ;
Tigyi, Gabor ;
Parrill, Abby L. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (21) :7457-7464